Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROCORTISONE

All products: general benefit

Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable

  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
  • Prednisone (Winpred): general benefit, Not a benefit

3 more in the class list below

Cortef · DIN 00030929 · 20mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortef · DIN 00030929 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2005-05-27 · brand CORTEF · ATC H02AB09 HYDROCORTISONE · form Tablet · route Oral · ingredients HYDROCORTISONE 20 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2958 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=433 · Verify on the e-Formulary ↗ (DIN 00030929)

Source record
DIN 00030929: Cortef Raw flags: sec3=Y Item: 680400007; group id 712; item number 1762; lccId None; manufacturer id PFI Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.4155; ministry $0.2958 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=433
Interchangeable products
Auro-Hydrocortisone · DIN 02524473 · $0.2958
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endocrine disorders, neoplastic diseases
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: METHYLPREDNISOLONE METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) 1 INDICATIONS pms-METHOTREXATE is indicated for Neoplastic diseases: • Choriocarcinoma: Methotrexate – as single chemotherapy or in combination with other drugs. PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph METHYLPREDNISOLONE · General benefit 1. Endocrine Disorders PM: https://pdf.hres.ca/dpd_pm/00080809.PDF; date 2025-06-13; DIN 00030988; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications CORTEF (hydrocortisone) is indicated for: • Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer. • Rheumatic Disorders: As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. • Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, acute rheumatic carditis, systemic dermatomyositis (polymyositis). • Dermatologic Diseases: pemphigus, bullous der… https://pdf.hres.ca/dpd_pm/00082414.PDF PM date: OCT 20, 2025 Source product: CORTEF; DIN 00030910; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.